Sustainability | October 14, 2022
JB Pharma publishes its maiden sustainability report
Since FY 2020 till FY 2022, the organisation has reduced energy consumption by 9.2%
Since FY 2020 till FY 2022, the organisation has reduced energy consumption by 9.2%
Availability of pharmaceutical-grade materials with broad API compatibility key to advancing drug delivery solutions
Agreement strengthens Evonik’s track record as leading contract development and manufacturing organization (CDMO)
DSCO has requested WHO to share at the earliest with CDSCO the report on establishment of causal relation to death with the medical products in question etc.
Brivaracetam is indicated for the treatment of partial-onset seizures in patients 4 years of age and older.
Amantadine Extended-Release capsules had annual sales of US $2.7 million in the United States according to IQVIA data
Mirabegron is indicated for the treatment of overactive bladder (OAB) with symptoms of urinary incontinence, urgency, and frequency
Funds raised will be used to develop technology and foster healthcare partnerships
The plant at Raleigh, North Carolina, USA owned by Aurolife Pharma has received an establishment inspection report (EIR)
Witnessing sizable consolidation (M& A) activity with Domestic Formulations and Hospitals being two areas wherein maximum M&A has occurred.
Subscribe To Our Newsletter & Stay Updated
